Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Interleukin-6 may not affect bone resorption marker CTX or bone formation marker P1NP in humans

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{d88aba2ff8d24e519812ec2294af586f,
title = "Interleukin-6 may not affect bone resorption marker CTX or bone formation marker P1NP in humans",
abstract = "Context: Interleukin 6 (IL-6) contributes to bone remodeling in preclinical studies. Clinical trials investigating the role of IL-6 in bone remodeling are limited.Objective: To investigate if IL-6 regulates bone remodeling in humans.Design: Plasma concentrations of the bone resorption marker carboxy-terminal type I collagen crosslinks (CTX) and of the bone formation marker procollagen type 1 N-terminal propeptide (P1NP) were measured during a mixed-meal tolerance test (MMTT) in 3 placebo-controlled human studies.Participants: Five healthy individuals participated in study 1; 52 obese individuals, in study 2; and 10 healthy individuals, in study 3.Interventions: Study 1 was a single-blinded crossover study consisting of a 1-h infusion of saline (placebo) or the IL-6 receptor antibody tocilizumab followed by an exercise bout. Study 2 was a randomized, double-blinded 12-week exercise training intervention study. Participants received infusions of saline or tocilizumab. Study 3 was a randomized, double-blinded, crossover study consisting of 30 min infusion of saline or IL-6.Main outcomes measures: Effect of IL-6 on CTX levels.Results: CTX was significantly (P < 0.01) decreased during MMTTs in all 3 studies. Treatment with tocilizumab did not affect exercise or meal induced changes in plasma CTX or P1NP concentrations acutely (study 1) or after a 12-week treatment period (study 2). Exogenous IL-6 had no effect on CTX or P1NP plasma concentrations (study 3).Conclusions: IL-6 may not regulate bone remodeling in humans.",
keywords = "Bone formation, Bone resorption, Interleukin-6",
author = "Lehrskov, {Louise L} and Sasha Kjeldsen and Lyngb{\ae}k, {Mark P} and Chirstensen, {Regitse H{\o}jgaard} and Anne-Sophie Wedell-Neergaard and Line S{\o}derlund and J{\o}rgensen, {Niklas Rye} and Rikke Krogh-Madsen and {Wewer Albrechtsen}, {Nicolai J} and Helga Ellingsgaard",
note = "{\textcopyright} Endocrine Society 2020.",
year = "2020",
month = sep,
day = "1",
doi = "10.1210/jendso/bvaa093",
language = "English",
volume = "4",
journal = "Journal of the Endocrine Society",
issn = "2472-1972",
publisher = "Endocrine Society",
number = "9",

}

RIS

TY - JOUR

T1 - Interleukin-6 may not affect bone resorption marker CTX or bone formation marker P1NP in humans

AU - Lehrskov, Louise L

AU - Kjeldsen, Sasha

AU - Lyngbæk, Mark P

AU - Chirstensen, Regitse Højgaard

AU - Wedell-Neergaard, Anne-Sophie

AU - Søderlund, Line

AU - Jørgensen, Niklas Rye

AU - Krogh-Madsen, Rikke

AU - Wewer Albrechtsen, Nicolai J

AU - Ellingsgaard, Helga

N1 - © Endocrine Society 2020.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Context: Interleukin 6 (IL-6) contributes to bone remodeling in preclinical studies. Clinical trials investigating the role of IL-6 in bone remodeling are limited.Objective: To investigate if IL-6 regulates bone remodeling in humans.Design: Plasma concentrations of the bone resorption marker carboxy-terminal type I collagen crosslinks (CTX) and of the bone formation marker procollagen type 1 N-terminal propeptide (P1NP) were measured during a mixed-meal tolerance test (MMTT) in 3 placebo-controlled human studies.Participants: Five healthy individuals participated in study 1; 52 obese individuals, in study 2; and 10 healthy individuals, in study 3.Interventions: Study 1 was a single-blinded crossover study consisting of a 1-h infusion of saline (placebo) or the IL-6 receptor antibody tocilizumab followed by an exercise bout. Study 2 was a randomized, double-blinded 12-week exercise training intervention study. Participants received infusions of saline or tocilizumab. Study 3 was a randomized, double-blinded, crossover study consisting of 30 min infusion of saline or IL-6.Main outcomes measures: Effect of IL-6 on CTX levels.Results: CTX was significantly (P < 0.01) decreased during MMTTs in all 3 studies. Treatment with tocilizumab did not affect exercise or meal induced changes in plasma CTX or P1NP concentrations acutely (study 1) or after a 12-week treatment period (study 2). Exogenous IL-6 had no effect on CTX or P1NP plasma concentrations (study 3).Conclusions: IL-6 may not regulate bone remodeling in humans.

AB - Context: Interleukin 6 (IL-6) contributes to bone remodeling in preclinical studies. Clinical trials investigating the role of IL-6 in bone remodeling are limited.Objective: To investigate if IL-6 regulates bone remodeling in humans.Design: Plasma concentrations of the bone resorption marker carboxy-terminal type I collagen crosslinks (CTX) and of the bone formation marker procollagen type 1 N-terminal propeptide (P1NP) were measured during a mixed-meal tolerance test (MMTT) in 3 placebo-controlled human studies.Participants: Five healthy individuals participated in study 1; 52 obese individuals, in study 2; and 10 healthy individuals, in study 3.Interventions: Study 1 was a single-blinded crossover study consisting of a 1-h infusion of saline (placebo) or the IL-6 receptor antibody tocilizumab followed by an exercise bout. Study 2 was a randomized, double-blinded 12-week exercise training intervention study. Participants received infusions of saline or tocilizumab. Study 3 was a randomized, double-blinded, crossover study consisting of 30 min infusion of saline or IL-6.Main outcomes measures: Effect of IL-6 on CTX levels.Results: CTX was significantly (P < 0.01) decreased during MMTTs in all 3 studies. Treatment with tocilizumab did not affect exercise or meal induced changes in plasma CTX or P1NP concentrations acutely (study 1) or after a 12-week treatment period (study 2). Exogenous IL-6 had no effect on CTX or P1NP plasma concentrations (study 3).Conclusions: IL-6 may not regulate bone remodeling in humans.

KW - Bone formation

KW - Bone resorption

KW - Interleukin-6

UR - http://www.scopus.com/inward/record.url?scp=85096485167&partnerID=8YFLogxK

U2 - 10.1210/jendso/bvaa093

DO - 10.1210/jendso/bvaa093

M3 - Journal article

C2 - 32793846

VL - 4

JO - Journal of the Endocrine Society

JF - Journal of the Endocrine Society

SN - 2472-1972

IS - 9

M1 - bvaa093

ER -

ID: 60694015